Facing the Challenges and Unknowns Posed by GLP-1 Receptor Agonist Medications - Webinar for Medical Leads
About this webinar Glucagon-like peptide-1 (GLP-1) is a hormone that plays important roles in regulating appetite and blood sugar levels. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a new group of drugs that were originally developed to treat type 2 diabetes and that are increasingly prescribed to manage weight. GLP-1 RAs have been shown to be very effective at lowering blood sugar levels, as well as demonstrating benefits for heart health and kidney function. However, there is a lack of evidence to inform whether GLP-1 RAs could be administered in populations with eating disorders.
In this webinar Dr Brown will provide an overview of how GLP-1RAs act in the brain to increase feeling of satiety as well as reduce hedonic aspects of eating behaviour such as craving. She will also cover what is known about the role of GLP-1 in stress and mood. Assoc/Prof Piya will then provide an overview of the use of GLP-1 receptor agonists medications in Type 2 diabetes and weight management. He will overview the clinical trial data to date and address factors clinicians should take into account when patients with an eating disorder seek guidance on GLP-1 RAs.